Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Welireg™ (belzutifan) – New Drug Approval – December 14, 2023 – The Food and Drug Administration approved belzutifan (Welireg™, Merck & Co., Inc.) for patients with advanced renal cell carcinoma…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Casgevy™ (exagamglogene autotemcel) – New Drug Approval – December 8, 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced that the U.S. Food and Drug Administration…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 05, 2023 Fluorescein Sodium Injection (Resolved) December 01, 2023 Azacitidine Injection (Currently in Shortage) Hydroxypropyl Cellulose…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ogsiveo™ (nirogacestat) Tablets – New Drug Approval – November 27, 2023 – The U.S. Food and Drug Administration approved Ogsiveo™ (nirogacestat) tablets for adult patients with progressing desmoid tumors who…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Truqap™ (capivasertib) Tablets – New Drug Approval – November 16, 2023 – AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) has been approved in the US for the treatment of…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ixchiq® (chikungunya vaccine, live) Injection – New Vaccine Approval – November 9, 2023 – The U.S. Food and Drug Administration approved Ixchiq®, the first chikungunya vaccine. Ixchiq® is approved for…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Voquezna® (vonoprazan) Tablets – New Drug Approval – November 1, 2023 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Loqtorzi™ (toripalimab-tpzi) Injection – New Drug Approval – October 27, 2023 – The Food and Drug Administration approved toripalimab-tpzi (Loqtorzi™, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Penbraya (meningococcal groups A, B, C, W, and Y vaccine) Injection – New Vaccine Approval – October 20, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Velsipity™ (etrasimod) Tablets – New Drug Approval – October 12, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod),…

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Cosentyx® (secukinumab) Injection – New Label Expansion – October 6, 2023 – Novartis, a global leader in immuno-dermatology and rheumatology, announced that the…